このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行固形悪性腫瘍患者におけるAZD5305 hADME (AZD5305)

2026年11月9日 更新者:AstraZeneca

進行性固形悪性腫瘍患者におけるサルパリブ (AZD5305) の絶対バイオアベイラビリティおよび [14C]-サルパリブ ([14C]-AZD5305) の吸収、分布、代謝、排泄 (ADME) を評価する第 I 相非盲検試験

This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of [14C]-Saruparib in patients with advanced solid malignancies.

This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable).

調査の概要

詳細な説明

This is an open-label, 2-part study in participants with advanced solid malignancies and will be conducted at multiple study sites.

Participants will be assessed for study eligibility prior to admission to the study site during a 28-day screening period. Participants will take part in both Parts A and B of the study.

Part A will assess the absolute bioavailability and evaluate the PK parameters of oral Saruparib and a radiolabelled IV microdose of [14C]-Saruparib

Participants will be admitted to the study site pre-dose of Part A and will remain resident at the study site for PK sampling and safety assessments.

A washout period will be observed between doses of Saruparib in Parts A and B.

Part B will assess the ADME of oral [14C]-Saruparib. Participants will be readmitted to the study site for Part B and will remain resident at the study site for excreta (urine, faeces, and any vomitus) collections, PK sampling, and safety assessments. Participants may be discharged from the study site prior to the last indicated day if both the following discharge criteria are met:

  1. ≥ 90% mass balance recovery, and
  2. < 1% of the total radioactive dose is recovered in combined excreta (urine and faeces) in 2 consecutive 24-hour periods.

Participants will return to the study site for a Follow-up Visit after the last dose of Saruparib which will include routine safety assessments. After the completion of Parts A and B, and following the Follow-up Visit, participants may be allowed further access to Saruparib.

Additional safety data collection will be conducted.

研究の種類

介入

入学 (推定)

8

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Liverpool、イギリス、L7 8YA
        • 募集
        • Research Site
      • Manchester、イギリス、M20 4BX
        • 募集
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male or female ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the ICF.
  2. Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
  3. ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to dosing.
  4. Predicted life expectancy ≥ 12 weeks.
  5. Adequate organ and marrow function as defined in the protocol
  6. Willingness and ability to comply with study and follow-up procedures.
  7. Able and willing to stay in hospital for specified residential periods following administration of Saruparib/[14C]-Saruparib
  8. Regular bowel movements
  9. Body weight within normal range specified in protocol
  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Reproduction
  11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol

Exclusion Criteria:

  1. Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). Specific screening for MDS/AML is not required.
  2. Participants with any known predisposition to bleeding
  3. Any history of persisting severe cytopenia due to any cause
  4. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of Saruparib.
  5. History of another primary malignancy, with some exceptions
  6. Persistent toxicities (CTCAE Grade ≥ 2), excluding alopecia and peripheral neuropathy, caused by previous anticancer therapy.
  7. Spinal cord compression or brain metastases for at least 4 weeks prior to start of study intervention unless asymptomatic and stable
  8. Abnormal cardiac function exclusions or cardiovascular disease
  9. History of arrhythmia
  10. Active HBV (positive HBsAg result) or HCV.
  11. Evidence of active and uncontrolled HIV infection.
  12. Active tuberculosis infection
  13. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  14. As judged by the investigator, any other evidence of diseases (such as severe or uncontrolled systemic diseases or active uncontrolled infections which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardise compliance with the protocol.
  15. Any prior treatment with Saruparib.
  16. Other anticancer therapy (chemotherapy, immunotherapy, hormonal anticancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is not permitted until the last PK sampling is completed.
  17. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
  18. Concomitant use of medications or herbal supplements known to be CYP3A4 strong inhibitors or inducers
  19. Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes
  20. Participants who have participated in another absorption, distribution, metabolism, and excretion study within 1 year prior to screening.
  21. Participation in another clinical study with a study intervention administered in the last 1 month or 5 half-lives prior to dosing, whichever is longer.
  22. Participants with a known hypersensitivity to Saruparib or any of the excipients of the product.
  23. Participants who have been administered any amount of a [14C]-labelled compound within the last 12 months.
  24. Use of tobacco- or nicotine-containing products or alcohol may be exclusionary
  25. Poor peripheral venous access (venous access via a port will be permitted).
  26. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  27. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  28. Previous enrolment in the present study.
  29. For female participants only: currently pregnant (confirmed with positive pregnancy test) or planning to become pregnant, breast-feeding, or intending to donate/retrieve ova before 6 months after the last dose of Saruparib.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Primary Treatment Arm - AZD5305

Part A will assess absolute bioavailability via oral administration of Saruparib (AZD5305) and IV [14C]-saruparib microtracer.

Part B will assess ADME via IV [14C]-saruparib administration

PARP-inhibitor

他の名前:
  • サルパリブ

IV radiolabeled microtracer

他の名前:
  • IV [14C]-サルパリブ マイクロトレーサー

IV radiolabeled PARP inhibitor

他の名前:
  • IV [14C]-サルパリブ (治療用量)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Absolute bioavailability (F) of Saruparib
時間枠:Day 4

Absolute bioavailability (F) of Saruparib

Day 4
Total radioactivity recovery in urine and faeces
時間枠:Day 8

Total radioactivity recovery in urine and faeces

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

AUCinf

Day 8
PK parameters characterized by AUCinf
時間枠:Day 4

AUCinf

Day 4
Ratio of AUCinf of plasma Saruparib relative to AUCinf of metabolite
時間枠:Day 4

Ratio of AUCinf of plasma Saruparib relative to AUCinf of metabolite

Day 4
Mass balance parameters as characterized by amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined)
時間枠:Day 8

Cumulative amount excreted in urine, faeces and total (urine and faeces combined)

Day 8
Amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the administered dose
時間枠:Day 8

Amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the administered dose.

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

AUClast

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

Cmax

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

tmax

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

t1/2(lambda)z

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

Ratio of AUCinf of plasma Saruparib relative to AUCinf of plasma total radioactivity

Day 8
Pharmacokinetics of Saruparib(Part B)
時間枠:Day 8

Ratio of AUCinf of whole blood total radioactivity relative to AUCinf of plasma total radioactivity

Day 8
PK parameters characterized by AUClast
時間枠:Day 4

AUClast

Day 4
PK parameters characterized by Cmax
時間枠:Day 4

Cmax

Day 4
PK parameters characterized by tmax
時間枠:Day 4

tmax

Day 4
PK parameters characterized by t1/2(lambda)z
時間枠:Day 4

t1/2(lambda)z

Day 4

二次結果の測定

結果測定
メジャーの説明
時間枠
Metabolic profiling of a single oral dose of [14C]-Saruparib (Part B)
時間枠:Day 8

Determining mass balance parameters following oral administration of a therapeutic dose containing 20uCi of 14C-AZD5305 followed by metabolite profiling and identification in plasma, urine, and feces to quantify the 14C-AZD5305 related material in each matrix to satisfy MIST considerations.

Day 8
Characterize the safety of Saruparib in participants with advanced solid malignancies by incidence and severity of AEs, laboratory abnormalities, 12-lead ECG abnormalities, vital signs abnormalities, physical examination findings
時間枠:Day 14

incidence and severity of AEs, -incidence of laboratory abnormalities (based on hematology, clinical chemistry, and urinalysis test results), -12-lead ECG abnormalities, vital signs abnormalities, physical examination findings

Day 14

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年4月2日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2027年2月8日

試験登録日

最初に提出

2024年7月30日

QC基準を満たした最初の提出物

2024年11月27日

最初の投稿 (実際)

2024年12月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する